1-8 of 8
Keywords: metformin
Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Biochem J (2023) 480 (1): 105–125.
Published: 13 January 2023
... are critically discussed. The effects of several anti-diabetic drugs, particularly metformin, on hepatic gluconeogenesis are also considered. We conclude that the main effect of AMPK activation pertinent to the control of hepatic gluconeogenesis is to antagonize glucagon signalling in the short-term...
Biochem J (2016) 473 (11): 1483–1501.
Published: 27 May 2016
... signalling with FSH or LH signalling at critical nodes are identified and the available evidence for such interactions in ovarian cells is discussed. Finally the action of the insulin-sensitizing drugs metformin and the thiazolidinedione rosiglitazone on follicular cells is reviewed. 1 To whom...
Biochem J (2015) 471 (3): 307–322.
Published: 16 October 2015
... of these drugs are already established, effectively enabling preclinical studies to be bypassed. Metformin is one such drug currently being investigated for novel applications. The present review provides a thorough and detailed account of our current understanding of the molecular pharmacology and signalling...
Biochem J (2014) 463 (3): e3–e5.
Published: 10 October 2014
...Eric Fontaine Metformin is the most widely prescribed drug used to treat patients affected by Type 2 diabetes. Metformin has also been shown to prevent some forms of cell death; however, evidence suggests that it may have anti-neoplastic properties. All of these effects have been attributed...
Biochem J (2014) 462 (3): 475–487.
Published: 22 August 2014
...Hannah R. Bridges; Andrew J. Y. Jones; Michael N. Pollak; Judy Hirst The biguanide metformin is widely prescribed for Type II diabetes and has anti-neoplastic activity in laboratory models. Despite evidence that inhibition of mitochondrial respiratory complex I by metformin is the primary cause...
Biochem J (2008) 412 (2): 211–221.
Published: 14 May 2008
... pathway by administration of metformin, phenformin or A-769662 to PTEN +/− mice significantly delayed tumour onset. We demonstrate that LKB1 is required for activators of AMPK to inhibit mTORC1 signalling as well as cell growth in PTEN-deficient cells. Our findings highlight, using an animal model...
Includes: Supplementary data
Biochem J (2008) 409 (2): 449–459.
Published: 21 December 2007
... © The Authors Journal compilation © 2008 Biochemical Society 2008 14-3-3 Akt substrate of 160 kDa (AS160) AMP-activated protein kinase (AMPK) metformin obesity protein kinase B (PKB) TBC1D1 Rabs are GTP-activated proteins that regulate the flow of vesicle traffic between...
Includes: Supplementary data